ERBB2 and ovarian cancer: In addition, apoptosis has also been reported for EGCG combined with cetuximab in TNBC xenograft models [13]; and for G28, in other HER2-positive breast cancer models both in vivo and in vitro, alone and combined with anti-HER drugs [10], and in several ovarian cancer models in a dose-dependent manner [41,42].